Lung adenocarcinoma (LUAD) is a refractory tumor with high incidence, high mortality, and easy development of drug resistance.
Represented by PD-L1, the rise of immunotherapy and multidrug combinations offers a reliable approach to treating LUAD.
However, there are still some patients with immunoresistance or insensitivity, and new combination therapies are still needed.
